Overview

Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease

Status:
Withdrawn
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
We aim to investigate the antiproteinuric effect of adding Dapagliflozin to the standard of care in children with proteinuria.
Phase:
Phase 4
Details
Lead Sponsor:
Children's Hospital of Fudan University
Treatments:
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Angiotensin-Converting Enzyme Inhibitors
Dapagliflozin